Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Izzo

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Alzheimer'S & Dementia (New York, N. Y.)|February 7, 2019
A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's diseaseMichael Grundman, Roger Morgan, Jason D Lickliter, et al.
Eneuro|October 8, 2020
Proceedings from the Fourth International Symposium on σ-2 Receptors: Role in Health and DiseaseNicholas J Izzo, Martí Colom-Cadena, Aladdin A Riad, et al.
ACS Medicinal Chemistry Letters|September 17, 2021
Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's DiseaseGilbert M Rishton, Gary C Look, Zhi-Jie Ni, et al.
Analytical Biochemistry|April 25, 2003
Determination of endogenous extracellular signal-regulated protein kinase by microchip capillary electrophoresisDustin E Starkey, Yasser Abdelaziez, Chong H Ahn, et al.
Alzheimer'S Research & Therapy|March 4, 2020
The clinical promise of biomarkers of synapse damage or loss in Alzheimer's diseaseMartí Colom-Cadena, Tara Spires-Jones, Henrik Zetterberg, et al.
Plos One|November 13, 2014
Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicityNicholas J Izzo, Jinbin Xu, Chenbo Zeng, et al.
Translational Neurodegeneration|May 12, 2023
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheterKelsie M LaBarbera, Yvette I Sheline, Nicholas J Izzo, et al.
Plos One|November 13, 2014
Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficitsNicholas J Izzo, Agnes Staniszewski, Lillian To, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 9, 2021
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modificationNicholas J Izzo, Carla M Yuede, Kelsie M LaBarbera, et al.
Acta Neuropathologica|February 6, 2024
Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer's diseaseMartí Colom-Cadena, Jamie Toombs, Elizabeth Simzer, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Alzheimer'S & Dementia (New York, N. Y.)|February 7, 2019
A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's diseaseMichael Grundman, Roger Morgan, Jason D Lickliter, et al.
Eneuro|October 8, 2020
Proceedings from the Fourth International Symposium on σ-2 Receptors: Role in Health and DiseaseNicholas J Izzo, Martí Colom-Cadena, Aladdin A Riad, et al.
ACS Medicinal Chemistry Letters|September 17, 2021
Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's DiseaseGilbert M Rishton, Gary C Look, Zhi-Jie Ni, et al.
Analytical Biochemistry|April 25, 2003
Determination of endogenous extracellular signal-regulated protein kinase by microchip capillary electrophoresisDustin E Starkey, Yasser Abdelaziez, Chong H Ahn, et al.
Alzheimer'S Research & Therapy|March 4, 2020
The clinical promise of biomarkers of synapse damage or loss in Alzheimer's diseaseMartí Colom-Cadena, Tara Spires-Jones, Henrik Zetterberg, et al.
Plos One|November 13, 2014
Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicityNicholas J Izzo, Jinbin Xu, Chenbo Zeng, et al.
Translational Neurodegeneration|May 12, 2023
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheterKelsie M LaBarbera, Yvette I Sheline, Nicholas J Izzo, et al.
Plos One|November 13, 2014
Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficitsNicholas J Izzo, Agnes Staniszewski, Lillian To, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 9, 2021
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modificationNicholas J Izzo, Carla M Yuede, Kelsie M LaBarbera, et al.
Acta Neuropathologica|February 6, 2024
Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer's diseaseMartí Colom-Cadena, Jamie Toombs, Elizabeth Simzer, et al.
Pageof 2